Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

98
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
98
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

121
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
121
Negative Regulator Molecules01:23

Negative Regulator Molecules

37.7K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
37.7K
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

580
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
580
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

114
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
114
Experimental RNAi02:15

Experimental RNAi

7.0K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advanced glycation end product accumulation and AGEs-RAGE axis biomarkers in plasma and synovial fluid are associated with osteoarthritis severity.

Biomolecules & biomedicine·2026
Same author

Equinatoxin II: How a Cationic Pore-Forming Sea Anemone Toxin Drives Nodal Swelling of Myelinated Nerve Fibers.

Marine drugs·2026
Same author

Brain Changes in Alcohol Induced Liver Cirrhosis Patients: Insights from Quantitative Susceptibility Mapping.

Biomedicines·2025
Same author

The Importance of Multifaceted Approach for Accurate and Comprehensive Evaluation of Oxidative Stress Status in Biological Systems.

Antioxidants (Basel, Switzerland)·2025
Same author

Enhancement of muscle activation during squat exercise: evaluation with magnetic resonance imaging.

European journal of applied physiology·2025
Same author

Short-Term Fasting Induces Hepatocytes' Stress Response and Increases Their Resilience.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Dec 3, 2025

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
12:40

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

10.6K

Aripiprazole reduces liver cell division.

Tinkara Pirc Marolt1, Barbara Kramar1, Klara Bulc Rozman1

  • 1Institute of Pathophysiology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Plos One
|October 26, 2020
PubMed
Summary
This summary is machine-generated.

Aripiprazole, used for schizophrenia and addiction, may cause liver injury. Therapeutically relevant concentrations reduce liver cell division, potentially explaining severe liver damage in patients with alcohol and cocaine abuse history.

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.5K
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.3K

Related Experiment Videos

Last Updated: Dec 3, 2025

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
12:40

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

10.6K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.5K
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.3K

Area of Science:

  • Hepatology
  • Pharmacology
  • Toxicology

Background:

  • Aripiprazole is a second-generation antipsychotic used for schizophrenia and addiction.
  • While generally well-tolerated, severe liver injury (hepatotoxicity) has been reported in patients with a history of alcohol and cocaine abuse.
  • These substances require enhanced liver self-regeneration, a process potentially impaired by aripiprazole.

Purpose of the Study:

  • To investigate the effects of aripiprazole on liver cell division.
  • To explore a potential mechanism for aripiprazole-induced hepatotoxicity in patients with a history of alcohol and cocaine abuse.

Main Methods:

  • In vitro study using therapeutically relevant concentrations of aripiprazole.
  • Assessment of hepatocyte (liver cell) proliferation rates.

Main Results:

  • Therapeutically relevant concentrations of aripiprazole significantly reduced the rate of hepatocyte division.
  • This effect was observed at concentrations equivalent to laboratory alert levels in patient serum.

Conclusions:

  • Reduced hepatocyte division by aripiprazole may be an underlying mechanism for severe liver injury in patients with a history of alcohol and cocaine abuse.
  • Close monitoring of liver function is crucial when aripiprazole is used concurrently with or in patients with a history of hepatotoxic substance abuse.